

PRIOR AUTHORIZATION FORM

Wegovy - Medicare

Unless otherwise indicated below, authorization quantities are limited to the manufacturer recommended dosage

**Select
Health**

P.O. Box 30196 • Salt Lake City, UT 84130
Important Plan Information

Complete online at www.selecthealth.org/pa or fax back to: 801-650-3170

For questions or clarifications, call: 801-442-9988 or 855-442-9988

Patient Information

Patient's Name:

Patient's Date of Birth:

Patient's ID:

Patient's Phone #:

Diagnosis Code(s):

Requesting Provider Information

Name:

Phone #:

NPI/DEA:

Fax #:

Address:

Supervising Physician (if requesting provider bills under a different provider)

Name:

NPI/DEA:

Servicing Provider Information (if different than requesting provider)

Name of provider or facility:

Phone number:

NPI/DEA:

Address:

Drug Name and Strength:

Directions / SIG:

☐ Urgent Request (24 hours)☐ Standard Request (72 hours)**Q1. What is the patient's diagnosis?**

- ☐ Established cardiovascular disease
- ☐ Noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)
- ☐ Other

Q2. If other, please specify:**Q3. Is this a reauthorization request?**

☐ Yes	☐ No
Q4. For reauthorization requests, has documentation been submitted showing the patient has responded adequately to therapy, as demonstrated by at least one of the following: ☐ Reduction in fibrosis score by at least 1 stage as determined by hepatology based on liver enzymes and FibroScan CAP ☐ MASH histological resolution ☐ None of the above	
Q5. For ASCVD is the prescribing physician a Cardiologist? ☐ Yes ☐ No	
Q6. Does the patient have established cardiovascular disease defined as history of any of the following? (Please check all that apply) ☐ Prior myocardial infarction ☐ Prior stroke ☐ Symptomatic peripheral arterial disease as evidenced by intermittent claudication with ankle-brachial index greater than 0.85, peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease ☐ None of the above	
Q7. Does the patient have a body mass index (BMI) of 27 or greater? ☐ Yes ☐ No	
Q8. Does the patient have noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults? ☐ Yes ☐ No	
Q9. If yes, has the diagnosis been confirmed by transient elastography (FibroScan) CAP OR liver biopsy? ☐ Yes ☐ No	
Q10. For MASH is the prescribing physician a Hepatologist or Gastroenterologist? ☐ Yes ☐ No	
Q11. Is the patient 18 years of age or older? ☐ Yes ☐ No	

Q12. Will Wegovy be used in combination with another GLP-1 Receptor Agonist? (tirzepatide, dulaglutide, etc)

☐ Yes

☐ No

Q13. Does the patient's alcohol intake exceed 2 glasses per day (30g total)?

☐ Yes

☐ No

Q14. Chart Notes are required for the request of this medication. Failure to provide chart notes will result in a delay in decision and/or denial. Did you attach relevant chart notes?

☐ Yes

☐ No

Q15. Additional comments:

**This form is intended for Select Health members only. All requests for preauthorization should be sent via fax to 1-801-650-3170
Missing, inaccurate, or incomplete information may cause a delay or denial of authorization.**

Prescriber Signature

Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document